小剂量罗红霉素对支气管扩张患者稳定期诱导痰炎症因子水平的影响

Effect of low dose roxithromycin on inflammatory factors in induced sputum of patients with bronchiectasis in stable phase

目的:探讨小剂量罗红霉素对支气管扩张患者稳定期诱导痰炎症因子水平的影响。方法:将160例稳定期支气管扩张患者随机分为观察组及对照组各80例,对照组患者给予常规治疗,观察组在对照组基础上给予小剂量罗红霉素,对比两组患者的临床症状评分、肺功能指标(用力1秒呼气量及用力肺活量),两组患者治疗前后痰液中的IL-6、IL-8、IL-10水平及不良反应。结果:治疗后,两组患者的临床症状积分均降低(P<0.05),且观察组低于对照组(P<0.05);治疗后,两组患者的IL-6、IL-8、IL-10水平均降低(P<0.05),且观察组低于对照组(P<0.05);治疗期间,两组患者均无不良反应发生。结论:小剂量罗红霉素可能通过降低痰液中IL-6、IL-8、IL-10水平来改善支气管扩张患者稳定期的临床症状,且不增加不良反应。

Objective:To investigate the effect of low dose roxithromycin on inflammatory factors in induced sputum of patients with bronchiectasis in stable phase.Methods: 160 patients with stable bronchiectasis were selected. According to the random number table method, all patients were divided into observation group and control group, 80 cases in each group. Patients in the control group were given routine treatment, while patients in the observation group were given low dose roxithromycin on the basis of the control group. The clinical symptom score, pulmonary function index(one second expiratory volume and forced vital capacity), levels of IL-6, IL-8 and IL-10 in sputum of two groups before and after treatment were compared. Adverse reactions during treatment between the two groups were compared.Results: After treatment, the scores of clinical symptoms in both groups were decreased, and the observation group was lower than the control group ( P <0.05). After treatment, the levels of IL-6, IL-8 and IL-10 in the two groups were decreased, and the level in the observation group was significantly lower than that in the control group ( P <0.05). During the treatment period, there were no adverse reactions in both groups.Conclusion: Low dose roxithromycin may improve the clinical symptoms of stable bronchiectasis patients by reducing the levels of IL-6, IL-8 and IL-10 in sputum without increasing adverse reactions.